Yuviwel Kit
NDC Package 73362-201-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Yuviwel (navepegritide) kits is yUVIWEL® is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. This formulation utilizes a kit delivery system. Marketed by Ascendis Pharma Endocrinology, Inc., this product is identified by NDC 73362-201 and is authorized under FDA application NDA219164.

Identification & Billing

NDC Package Code
73362-201-01
Package Description
4 BOX in 1 CARTON / 1 KIT in 1 BOX (73362-201-02) * 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS (73362-205-01) * 1 SOLUTION in 1 SYRINGE, GLASS (73362-801-01)
Product Code
73362-201
11-Digit Billing Format
73362020101
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Yuviwel
Non-Proprietary Name
Navepegritide
Dosage Form
Kit - A packaged collection of related material.
Usage Information
YUVIWEL® is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Regulatory & Marketing

Labeler Name
Ascendis Pharma Endocrinology, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA219164
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
02-27-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73362-201-01 identifies a specific commercial package of 4 box in 1 carton / 1 kit in 1 box (73362-201-02) * 1 injection, powder, lyophilized, for solution in 1 vial, glass (73362-205-01) * 1 solution in 1 syringe, glass (73362-801-01) of Yuviwel, a human prescription drug labeled by Ascendis Pharma Endocrinology, Inc.. This kit is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ascendis Pharma Endocrinology, Inc. on February 27, 2026. The current certification is valid through December 31, 2027.

How is this Ascendis Pharma Endocrinology, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73362020101. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
73362-201-01
11-Digit CMS (5-4-2)
73362-0201-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.